Trinity Biotech Announces Amended Credit Agreement with Perceptive to Enhance Liquidity and Drive Transformation Plan

Core Viewpoint - Trinity Biotech plc has amended agreements with its primary lender, Perceptive Advisors, to enhance liquidity and support its Comprehensive Transformation Plan, focusing on continuous glucose monitoring technology and operational efficiency [1][2][4][5]. Financial Agreements - A deferred payment of $5 million related to the acquisition of Waveform Technologies' biosensor assets has been extended to November 2025, providing greater financial flexibility [2]. - An additional liquidity of approximately$5.5 million has been secured through cash and payment-in-kind interest, strengthening the company's financial position during its transformation [2]. - Trinity Biotech has granted Perceptive Advisors 1.5 million additional warrants to purchase the company's American Depositary Shares (ADS) and repriced existing ADS warrants at $0.80 per ADS [2]. Transformation Plan - The additional liquidity will support the Comprehensive Transformation Plan aimed at achieving long-term profitability through operational efficiency and innovation [4]. - A significant milestone includes the World Health Organization (WHO) approval for transferring late-stage manufacturing of TrinScreen HIV and Uni-Gold HIV to a lower-cost offshore partner, demonstrating the company's strategic execution capabilities [4]. Future Outlook - The company is well-positioned for sustainable growth and market expansion, particularly with its continuous glucose monitoring technology developed from the Waveform Technologies acquisition [7]. - The CEO emphasized the importance of these amendments in creating a stronger financial foundation and supporting critical initiatives, including CGM technology development [5].